Recently, a new class of therapeutics that disable the neonatal Fc receptor (FcRn), which protects IgG from degradation, has emerged to treat IgG-mediated autoimmune disease. 4,5 Here, we review ...

Previous studies established defective Fc receptor mediated clearance in patients with systemic lupus erythematosis (SLE), a disorder associated with circulating immune complexes (CIC).